EUCTR2004-001955-12-ES进行中（未招募）1 期
A double blind, placebo controlled, parallel group, multicenter study to assess the duration of action, safety and toleration of differing doses and combinations of immediate and modified release formulations of UK-369,003 and Cialis compared to placebo in adult male subjects with erectile dysfunction. - N/A
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- pfizer s.a
- 入组人数
- 335
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •1. Subjects who have given written informed consent to participate in the study.
- •2. Male subjects 18 to 65 years of age.
- •3. Documented clinical diagnosis of erectile dysfunction (ED) of at least 6 months duration. ED is defined as the inability to attain and/or maintain penile erection sufficient for satisfactory performance1. There must be documentation (clinical observational and/or anecdotal complaints by the subject) of erectile dysfunction of at least 6 months duration. Original and/or photocopies of the subject’s medical records that provide this documentation must be available for review as source documents. A letter from the treating or referring physician attesting to the fact that the subject has had erectile dysfunction for at least 6 months will be considered sufficient documentation.
- •4. Subjects who have previously responded successfully to an approved phosphodiesterase Type 5 inhibitor and were treated for a minimum of 2 months at a stable dose and have not experienced a severe or serious treatment related adverse event. The subjects must be willing to discontinue their treatment of the prescribed PDE 5 inhibitor for the duration of the study.
- •5. Subjects must be in a stable sexual relationship for at least 6 months and willing to attempt sexual intercourse at least once per week on average.
- •6. Subjects who are willing and able to comply with scheduled visits, treatment plan,
- •laboratory tests and other trial procedures.
- •Are the trial subjects under 18?
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years)
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Subjects with hypotension (BP<90/50 mm/hg).
- •2. Subjects with increased susceptibility to vasodilators including those with left ventricular outflow obstruction (eg, hypertrophic obstructive cardiomyopathy).
- •3. Subjects in whom sexual activity is inadvisable in the opinion of the investigator (Refer to Recommendations of the Princeton Consensus Panel, 20008 in Appendix 3 of the protocol).
- •4. Subjects at risk of priapism eg, sickle cell disease, multiple myeloma, myeloproliferative disorders (eg, myeloid leukemia, polycythemia, thrombocythemia).
- •5. Subject with a history of hypersensitivity to study drug and their excipients or known allergy to PDE5 inhibitors.
- •6. Subjects who have any medical (including known history of major hematological, renal, vascular, or hepatic abnormalities) or psychological condition or social circumstances that would impair their ability to participate reliably in the study, or those who increase the risk to themselves or others by participating.
- •7. Subjects with any relevant clinically significant abnormalities on the screening physical examination or laboratory tests (refer to Appendix 1, Appendix 2 and Appendix 3 of the protocol).
- •8. Subjects who intend to donate blood or blood products during the period of the study or 1 month following completion.
- •9. Subjects who have received an investigational drug within the last month prior to the screening visit.
- •10. Subjects who are receiving concomitant treatment with CYP3A4 inhibitors
- •(eg, saquinavir or ketoconazole respectively).
- •11. Subjects with known hereditary degenerative retinal disorders such as retinitis
- •pigmentosa.
- •12. Subjects currently treated with alpha-blockers.
- •13. Subjects who are currently prescribed and/or taking nitrates or nitric oxide donors in any form (oral, sublingual, buccal, transdermal, inhalational or aerosols)
研究者
相似试验
尚未招募
不适用
Clinical investigation on effects of FSFW0121 on appetite and weight management in overweight/obese subjects.CTRI/2021/12/038615Akay Natural Ingredients Pvt Ltd
进行中（未招募）
不适用
A double blind, placebo controlled, parallel group study with an open label reference arm to assess the effects of intravenously administered AIN457 on ozone induced neutrophilia compared to placebo and oral corticosteroid in healthy volunteersHealthy volunteersEUCTR2008-002854-39-DEovartis Pharma Services AG24
进行中（未招募）
不适用
A double blind, placebo controlled, parallel group, multicenter study to assess the duration of action, safety and toleration of differing doses and combinations of immediate and modified release formulations of UK-369,003 and Cialis compared to placebo in adult male subjects with erectile dysfunction. - N/AMale Erectile DysfunctionEUCTR2004-001955-12-DEPfizer Pharma GmbH335
进行中（未招募）
1 期
STEMALS-IIEUCTR2014-002228-28-ITniversità degli Studi di Torino e Azienda Ospedaliera Città della Salute e della Scienza di Torino90
尚未招募
不适用
A clinical study to evaluate the safety and efficacy of VISPO in healthy subjects.CTRI/2021/12/038621Vidya Herbs Pvt Ltd